Loyola University of Chicago

Marlon Ray Lutz, Jr

Daniel Paul Becker

Andria M Panagopoulos

Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described.

Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy

Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase ('MMP') inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described. 

Tribenzo-1,4,7-triazacyclononane and derivatives thereof having a formula (I) are disclosed. Methods of making tribenzo-1,4,7-triazacyclononane and related compounds also are disclosed. 

Growing community of inventors

Grayslake, IL, United States of America

Marlon Ray Lutz, Jr